Dow Jones Newswires: AstraZeneca: Studies show antibody reduces COVID risk


AstraZeneca PLC said Thursday that Phase 3 trials on its AZD7442 antibody combination confirmed that the treatment reduces risk of developing symptomatic Covid-19.

The pharmaceutical company AZN, +0.17% AZN, -0.66% said the analysis of its continuing trial evaluating a median six months of participant follow-up revealed that one dose of AZD7442 showed 83% reduced symptomatic Covid-19 risk and no severe disease or deaths.

A separate trial in patients with mild-to-moderate Covid-19 showed that a larger dose of AZD7442 reduced risk of severe Covid-19 or death by 88% compared to placebo, in patients who had been symptomatic for three days or fewer at the time of the treatment.

“These compelling results give me confidence that this long-acting antibody combination can provide my vulnerable patients with the long-lasting protection they urgently need to finally return to their everyday lives,” Hugh Montgomery, a professor at University College London and AZD7442 principal investigator, said.

Write to Jaime Llinares Taboada at; @JaimeLlinaresT

This article was originally published by Read the original article here.

Previous articleAstraZeneca says Phase 3 trials on COVID antibody treatment confirm efficacy
Next articleNOV reinstates quarterly dividend, last paid in March 2020


Please enter your comment!
Please enter your name here